Q2 2025 · 13F-HR
venBio Partners LLCholdings as filed
Filed 2025-08-14 · accession 0000905148-25-002929
$114.8M
Reported value
6
Positions
2025-06-30
Period end
The Brief · venBio Partners LLC · Q2 2025
AI · grounded in 13F
venBio Partners LLC established a new position in PHARVARIS N V PHVS valued at $75.5M. The fund also initiated stakes in HARMONY BIOSCIENCES HLDGS IN HRMY for $15.5M and ALUMIS INC ALMS for $13.9M. Additional new positions include LYELL IMMUNOPHARMA INC LYEL, ALX ONCOLOGY HLDGS INC ALXO, and ARTIVA BIOTHERAPEUTICS INC ARTV.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | PHARVARIS N V | $75.5M | 65.8% | 4,289,304 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $15.5M | 13.5% | 489,194 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $13.9M | 12.1% | 4,619,803 | Common | SOLE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC | $4.2M | 3.65% | 473,479 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $4.0M | 3.51% | 9,699,925 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $1.7M | 1.51% | 1,148,975 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.